However, despite the similar gene module identification methods used and the strong correlation between the Immunity metagene and the Immunity2 metagene previously described by our team for TNBC [3], the Immunity metagene was predictive of the response to chemotherapy in HER2-positive BC, whereas the Immunity2 metagene was not predictive of the response to chemotherapy in TNBC. Here, ERBB2 is linked to breast cancer.